- Home
- PCG vs IQV Comparison
PCG vs IQV Comparison
Compare PCG & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCG | IQV |
|---|---|---|
| Founded | 1905 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0B | 36.4B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PCG | IQV |
|---|---|---|
| Price | $15.32 | $224.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $21.05 | ★ $237.59 |
| AVG Volume (30 Days) | ★ 26.0M | 1.4M |
| Earning Date | 10-23-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.19 | ★ 7.30 |
| Revenue | ★ $24,762,000,000.00 | $15,904,000,000.00 |
| Revenue This Year | $4.23 | $6.14 |
| Revenue Next Year | $4.68 | $5.35 |
| P/E Ratio | ★ $12.90 | $30.80 |
| Revenue Growth | N/A | ★ 3.85 |
| 52 Week Low | $12.97 | $134.65 |
| 52 Week High | $21.00 | $234.30 |
Technical Indicators
Market Signals| Indicator | PCG | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 56.47 |
| Support Level | $15.06 | $225.54 |
| Resistance Level | $16.20 | $230.80 |
| Average True Range (ATR) | 0.40 | 5.82 |
| MACD | -0.10 | -0.30 |
| Stochastic Oscillator | 16.19 | 52.39 |
Price Performance
Historical ComparisonAbout PCG Pacific Gas & Electric Co.
PG&E is a holding company whose main subsidiary is Pacific Gas and Electric, a regulated utility operating in Central and Northern California that serves 5.3 million electricity customers and 4.6 million gas customers in 47 of the state's 58 counties. PG&E operated under bankruptcy court supervision between January 2019 and June 2020. In 2004, PG&E sold its unregulated assets as part of an earlier postbankruptcy reorganization.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.